Regeneron Phase III Stumble Shows RSV Market Is No Child's Play
Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.
You may also be interested in...
The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
Companies wanting more guidance on how to go about developing new vaccines and treatments for respiratory syncytial viral infections will be interested in a new document that has just been put out for consultation by the European Medicines Agency.